Evidence map›Paper›PMID 27271583›Full record

ArticleMolecules (Basel, Switzerland)2016

Aqueous Extract of Paris polyphylla (AEPP) Inhibits Ovarian Cancer via Suppression of Peroxisome Proliferator-Activated Receptor-Gamma Coactivator (PGC)-1alpha.

Chia-Woei Wang, Cheng-Jeng Tai, Chen-Yen Choong, Yu-Chun Lin, Bao-Hong Lee, Yeu-Ching Shi, Chen-Jei Tai

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 32 citations in OpenAlex.

  1. Frontiers in pharmacology · 2025
    Review
  2. Review
  3. Plants (Basel, Switzerland) · 2023
    Article
  4. Article
  5. Article
  6. The Fruits ofMolecules (Basel, Switzerland) · 2021
    Article
  7. Article
  8. Article
  9. Molecules (Basel, Switzerland) · 2019
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Chia-Woei WangDepartment of Obstetrics and Gynecology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11042, Taiwan. cwwang@ms4.hinet.net.
Cheng-Jeng TaiDivision of Hematology and Oncology, Department of Internal Medicine, Taipei Medicine University Hospital, Taipei 11031, Taiwan. cjtai@tmu.edu.tw.
Chen-Yen ChoongDepartment of Obstetrics and Gynecology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11042, Taiwan. chenyen_318@hotmail.com.
Yu-Chun LinTaiwan Indigena Botanica Co., Ltd., Taipei 11031, Taiwan. doclin10@gmail.com.
Bao-Hong LeeDivision of Hematology and Oncology, Department of Internal Medicine, Taipei Medicine University Hospital, Taipei 11031, Taiwan. f96b47117@ntu.edu.tw.
Yeu-Ching ShiTaiwan Indigena Botanica Co., Ltd., Taipei 11031, Taiwan. jasmineycs@yahoo.com.tw.
Chen-Jei TaiDepartment of Obstetrics and Gynecology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11042, Taiwan. d94b42005@ntu.edu.tw.
Taipei Medical University Hospital · TWTaipei Medical University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemotherapy, a major approach was used in carcinoma treatment, always involves the development of drug resistance as well as side-effects that affect the quality of patients' lives. An association between epithelial-mesenchymal transition (EMT) and chemotherapy resistance was established recently. We demonstrate in this paper that the aqueous extract of Paris polyphylla (AEPP)-a traditional Chinese medicine-can be used in various cancer types for suppression of carcinogenesis. We evaluated the suppressions of EMT and mitochondrial activity by AEPP treatment in a high-glucose (HG) induced-human ovarian carcinoma cell line (OVCAR-3 cells). The mitochondrial morphology was investigated using MitoTracker Deep Red FM staining. Our results indicated that AEPP reduced the viability of OVCAR-3 cells considerably through induction of apoptosis. However, this inhibitory potential of AEPP was attenuated by HG induction in OVCAR-3 cells. The levels of estrogen-related receptor (ERR)-alpha activator and peroxisome proliferator-activated receptor-gamma coactivator (PGC)-1alpha were elevated by HG induction, but were suppressed by AEPP treatment. Down-regulations of cell survival and EMT were oberved in OVCAR-3 cells through suppression of PGC-1alpha by AEPP treatment. These results were confirmed through PGC-1alpha knockdown and overexpression in OVCAR-3 cells. Thus, AEPP can be beneficial for treating ovarian cancer and has potential for development of an integrative cancer therapy against ovarian cancer proliferation, metastasis, and migration.

Indexed as

ApoptosisCell ProliferationCell SurvivalFemaleGene Expression Regulation, NeoplasticHumansMedicine, Chinese TraditionalMelanthiaceaeOvarian NeoplasmsPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaPlant ExtractsPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaPlant ExtractsPPARGC1A protein, humanepithelial-mesenchymal transition (EMT)high glucose inductionovarian cancerParis polyphyllaperoxisome proliferator-activated receptor-gamma coactivator (PGC)-1alpha

Identifiers

PMID27271583
PMCPMC6273164
OpenAlexW2415249010

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.